ABSTRACT
The PFA-100 (platelet function analyser; Dade-Behring, Marburg, Germany) is a relatively new tool for the investigation of primary hemostasis. Recent studies have shown its utility as a screening tool for investigating various platelet disorders and possible von Willebrand disorder (vWD), both in the initial investigation and in subsequent therapeutic monitoring of desmopressin therapy. This article reviews current findings with respect to the identification of vWD, and highlights both the benefits and the limitations of its clinical utility. In brief, sensitivity to vWD types 2A, 2B, 2M, and 3 is > 98%, but overall sensitivity to vWD (types 1, 2A, 2B, 2M, and 3 combined) is ~85 to 90%. Ultimately, the high sensitivity of the PFA-100 to vWD and its simplicity of use provide its greatest strengths. However, because it is a global test system, and also sensitive to low hematocrit, low platelet counts, and platelet dysfunction (both congenital and acquired; e.g., secondary to medication such as aspirin) it must be recognized that the PFA-100 is neither specific for, nor predictive of, any particular disorder (inclusive of vWD). Nevertheless, used appropriately, the PFA-100 can be considered a worthwhile addition to the hemostasis laboratory involved in the diagnosis or therapeutic monitoring of vWD, and a normal PFA-100 result can be used with some confidence to exclude severe vWD.
KEYWORDS
Platelet function - PFA-100 - bleeding disorders - von Willebrand Factor (vWF) - von Willebrand disease - von Willebrand disorder (vWD) - laboratory assessment - diagnosis - review
REFERENCES
-
1
Kundu S K, Heilmann E J, Sio R, Garcia C, Davidson R M, Ostgaard R A.
Description of an in-vitro platelet function analyser: PFA-100®
.
Semin Thromb Hemost.
1995;
21(suppl 2)
106-112
-
2
Mammen E F, Alshameeri R S, Comp P C.
Preliminary data from a field trial of the PFA-100® system.
Semin Thromb Hemost.
1995;
21(suppl 2)
113-120
-
3
Harrison P.
Progress in the assessment of platelet function.
Br J Haematol.
2000;
111
733-744
-
4
Favaloro E J.
Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations.
Haemophilia.
2001;
7
170-179
-
5
Jilma B.
Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction.
J Lab Clin Med.
2001;
138
152-163
-
6
Harrison P.
The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults.
Br J Haematol.
2005;
130
3-10
-
7
Favaloro E J.
Clinical utility of the PFA-100®
.
Curr Opin Hematol.
2002;
9
407-415
-
8
Favaloro E J.
Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.
Blood Rev.
1999;
13
185-204
-
9
Favaloro E J.
Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder.
Best Pract Res Clin Haematol.
2001;
14
299-319
-
10
Favaloro E J.
Laboratory identification of von Willebrand Disease: technical and scientific perspectives.
Semin Thromb Hemost.
2006;
32
456-471
-
11
Dalby M C, Davidson S J, Burman J F, Davies S W.
Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser.
Platelets.
2000;
11
320-324
-
12
Feuring M, Christ M, Roell A et al..
Alterations in platelet function during the ovarian cycle.
Blood Coagul Fibrinolysis.
2002;
13
443-447
-
13
Lippi G, Franchini M, Brocco G, Manzato F.
Influence of the ABO blood type on the platelet function analyzer PFA-100.
Thromb Haemost.
2001;
85
369-370
-
14
Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V.
Influence of ABO blood groups on primary hemostasis.
Transfusion.
2001;
41
56-60
-
15
Nitu-Whalley I C, Lee C A, Brown S A, Riddell A, Hermans C.
The role of the platelet function analyser (PFA-100) in the characterization of patients with von Willebrand's disease and its relationships with von Willebrand factor and the ABO blood group.
Haemophilia.
2003;
9
298-302
-
16
Carcao M D, Blanchette V S, Dean J A et al..
The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children.
Br J Haematol.
1998;
101
70-73
-
17
Dean J A, Blanchette V S, Carcao M D et al..
von Willebrand Disease in a paediatric-based population-comparison of type 1 diagnostic criteria and use of the PFA-100® and a von Willebrand factor/collagen-binding assay.
Thromb Haemost.
2000;
84
401-409
-
18
Fressinaud E, Veyradier A, Truchaud F et al..
Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.
Blood.
1998;
91
1325-1331
-
19
Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D.
Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates.
Br J Haematol.
1999;
106
777-783
-
20
Mammen E F, Comp P C, Gosselin R et al..
PFA-100 system: a new method for assessment of platelet dysfunction.
Semin Thromb Hemost.
1998;
24
195-202
-
21
Cattaneo M, Federici A B, Lecchi A et al..
Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.
Thromb Haemost.
1999;
82
35-39
-
22
Favaloro E J, Facey D, Henniker A.
Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders.
Am J Hematol.
1999;
62
165-174
-
23
Favaloro E J, Kershaw G, Bukuya M, Hertzberg M, Koutts J.
Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy: efficacy of the PFA-100® and VWF:CBA as combined diagnostic strategies.
Haemophilia.
2001;
7
180-189
-
24
Favaloro E J.
Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study of 148 patients-a rebuttal.
J Thromb Haemost.
2004;
2
2280-2282
-
25
Harrison P, Robinson M S, Mackie I J et al..
Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis.
Blood Coagul Fibrinolysis.
1999;
10
25-31
-
26
Harrison P, Robinson M, Liesner R et al..
The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction.
Clin Lab Haematol.
2002;
24
225-232
-
27
Kerenyi A, Schlammadinger A, Ajzner E et al..
Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function.
Thromb Res.
1999;
96
487-492
-
28
Schlammadinger A, Kerenyi A, Muszbek L, Boda Z.
Comparison of the O'Brien filter test and the PFA-100 platelet analyser in the laboratory diagnosis of von Willebrand's disease.
Thromb Haemost.
2000;
84
88-92
-
29
Meskal A, Vertessen F, Van der Planken M, Berneman Z N.
The platelet function analyzer (PFA-100) may not be suitable for monitoring the therapeutic efficiency of von Willebrand concentrate in type III von Willebrand disease.
Ann Hematol.
1999;
78
426-430
-
30
Ortel T L, James A H, Thames E H, Moore K D, Greenberg C S.
Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center.
Thromb Haemost.
2000;
84
93-97
-
31
Buyukasik Y, Karakus S, Goker H et al..
Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease.
Blood Coagul Fibrinolysis.
2002;
13
349-353
-
32
Wuillemin W A, Gasser K M, Zeerleder S S, Lammle B.
Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency.
Swiss Med Wkly.
2002;
132
443-448
-
33
Cariappa R, Wilhite T R, Parvin C A, Luchtman-Jones L.
Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems.
J Pediatr Hematol Oncol.
2003;
25
474-479
-
34
Posan E, McBane R D, Grill D E, Motsko C L, Nichols W L.
Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice.
Thromb Haemost.
2003;
90
483-490
-
35
Quiroga T, Goycoolea M, Munoz B et al..
Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients.
J Thromb Haemost.
2004;
2
892-898
-
36
Favaloro E J, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro J WC.
Reassessment of ABO-blood group, gender and age on laboratory parameters used to diagnose von Willebrand Disorder (VWD): potential influence on the diagnosis versus the potential association with risk of thrombosis.
Am J Clin Pathol.
2005;
124
910-917
-
37
Franchini M, Gandini G, Manzato F, Lippi G.
Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease.
Haematologica.
2002;
87
670
-
38
Francis J L, Francis D, Larson L, Helms E, Garcia M.
Can the platelet function analyser (PFA) -100 test substitute for the template bleeding time in routine clinical practice.
Platelets.
1999;
10
132-136
-
39
Favaloro E J.
von Willebrand factor (VWF) collagen binding (activity) assay (VWF:CBA) in the diagnosis of von Willebrand's disorder (VWD): a 15-year journey.
Semin Thromb Hemost.
2002;
28
191-202
-
40
Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert U T, Hellstern P.
Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals.
Br J Haematol.
2005;
130
759-767
-
41
Cattaneo M.
Are the bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature?.
J Thromb Haemost.
2004;
2
890-891
Dr.
Emmanuel J Favaloro
Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR)
Westmead Hospital, SWAHS, Westmead, New South Wales, 2145, Australia
Email: emmanuel@icpmr.swahs.nsw.gov.au
